S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NASDAQ:ESTA

Establishment Labs (ESTA) Competitors

$66.39
-0.33 (-0.49%)
(As of 06/7/2023 ET)
Compare
Today's Range
$65.06
$66.82
50-Day Range
$64.32
$75.89
52-Week Range
$44.03
$79.88
Volume
132,966 shs
Average Volume
143,371 shs
Market Capitalization
$1.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$95.20

ESTA vs. AVNS, ENOV, IRWD, VRNA, RCKT, FGEN, XNCR, SLRN, RDNT, and KDNY

Should you be buying Establishment Labs stock or one of its competitors? The main competitors of Establishment Labs include Avanos Medical (AVNS), Enovis (ENOV), Ironwood Pharmaceuticals (IRWD), Verona Pharma (VRNA), Rocket Pharmaceuticals (RCKT), FibroGen (FGEN), Xencor (XNCR), Acelyrin (SLRN), RadNet (RDNT), and Chinook Therapeutics (KDNY). These companies are all part of the "medical" sector.

Establishment Labs vs.

Establishment Labs (NASDAQ:ESTA) and Avanos Medical (NYSE:AVNS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, community ranking, dividends, earnings, institutional ownership and profitability.

In the previous week, Avanos Medical had 2 more articles in the media than Establishment Labs. MarketBeat recorded 3 mentions for Avanos Medical and 1 mentions for Establishment Labs. Avanos Medical's average media sentiment score of 1.59 beat Establishment Labs' score of 0.78 indicating that Avanos Medical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Establishment Labs
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Avanos Medical
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Establishment Labs currently has a consensus price target of $95.20, suggesting a potential upside of 43.40%. Avanos Medical has a consensus price target of $30.25, suggesting a potential upside of 18.26%. Given Establishment Labs' stronger consensus rating and higher possible upside, analysts plainly believe Establishment Labs is more favorable than Avanos Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Establishment Labs
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Avanos Medical
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Avanos Medical has a net margin of 5.34% compared to Establishment Labs' net margin of -47.84%. Avanos Medical's return on equity of 6.11% beat Establishment Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Establishment Labs -47.84% -422.08% -32.77%
Avanos Medical 5.34% 6.11% 4.43%

Establishment Labs has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Avanos Medical has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Avanos Medical has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Establishment Labs$161.70 million10.57-$75.21 million-$3.31-20.06
Avanos Medical$820 million1.46$50.50 million$0.9227.80

Establishment Labs received 22 more outperform votes than Avanos Medical when rated by MarketBeat users. Likewise, 60.23% of users gave Establishment Labs an outperform vote while only 56.64% of users gave Avanos Medical an outperform vote.

CompanyUnderperformOutperform
Establishment LabsOutperform Votes
103
60.23%
Underperform Votes
68
39.77%
Avanos MedicalOutperform Votes
81
56.64%
Underperform Votes
62
43.36%

75.3% of Establishment Labs shares are owned by institutional investors. Comparatively, 92.1% of Avanos Medical shares are owned by institutional investors. 12.6% of Establishment Labs shares are owned by insiders. Comparatively, 2.9% of Avanos Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Avanos Medical beats Establishment Labs on 10 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ESTA vs. The Competition

MetricEstablishment LabsSurgical appliances & supplies IndustryMedical SectorNASDAQ Exchange
Market Cap$1.71B$7.51B$4.53B$6.22B
Dividend YieldN/A1.42%5.94%6.48%
P/E Ratio-20.0621.62100.5612.38
Price / Sales10.5771.113,485.0588.81
Price / CashN/A22.7591.96104.84
Price / Book-195.263.954.725.29
Net Income-$75.21M$118.01M$117.43M$192.85M
7 Day Performance2.90%89.65%6.23%4.94%
1 Month Performance-1.94%77.20%4.45%5.93%
1 Year Performance3.06%18.31%12.18%1.62%

Establishment Labs Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVNS
Avanos Medical
2.4806 of 5 stars
$23.95
+2.4%
$30.25
+26.3%
-10.1%$1.12B$814.30M26.034,044News Coverage
ENOV
Enovis
1.7438 of 5 stars
$53.01
-0.5%
$64.88
+22.4%
-17.2%$2.89B$1.56B-55.226,800
IRWD
Ironwood Pharmaceuticals
2.142 of 5 stars
$10.75
-0.6%
$15.67
+45.7%
-6.1%$1.66B$410.60M10.64219
VRNA
Verona Pharma
1.8514 of 5 stars
$20.90
-2.3%
$29.33
+40.4%
+306.9%$1.65B$460,000.00-21.7724Analyst Report
Positive News
RCKT
Rocket Pharmaceuticals
2.3463 of 5 stars
$20.65
-2.6%
$51.09
+147.4%
+80.7%$1.66BN/A-6.16151
FGEN
FibroGen
2.2159 of 5 stars
$17.11
+2.5%
$23.40
+36.8%
+96.9%$1.67B$140.73M-5.23566Options Volume
News Coverage
XNCR
Xencor
2.0671 of 5 stars
$27.09
-0.6%
$45.33
+67.3%
+28.1%$1.64B$164.58M-11.58254Positive News
SLRN
Acelyrin
1.9689 of 5 stars
$18.17
-5.7%
N/AN/A$1.68BN/A0.00N/A
RDNT
RadNet
1.8653 of 5 stars
$28.93
+0.0%
$30.00
+3.7%
+58.4%$1.69B$1.43B-120.549,067Insider Selling
KDNY
Chinook Therapeutics
1.9804 of 5 stars
$24.25
+4.0%
$35.83
+47.8%
+51.2%$1.62B$6.13M-7.60138

Related Companies and Tools

This page (NASDAQ:ESTA) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -